651.675.0300
rmueller@biotherapharma.com

952.922.1445 x10
jbarrow@coolibar.com

johnh@discoverygenomics.net

dan.miller@excorp.com

Gyrx™, LLC, a Jacksonville manufacturer, lead by a proven management team, has developed new surgical devices. The devices have several advantages over devices currently available. The devices are less invasive, reduces postoperative pain, improves patient cosmesis and utilize patent pending titanium clip technology. The surgical ligation product, Visu-Loc™ has been released to market. The male sterilization device, TiClip™, will be marketed six months after funding The company is seeking $1 million to fund the production and roll out of the general surgery and male sterilization devices.

HEALTH CAPITAL MANAGEMENT

picture not available

Founded in 1998, Lucigen Corporation (Middleton, WI) has developed unique specialty products for gene cloning and genomics; and innovative technologies for enzyme discovery. The Company currently manufactures and sells more than 50 gene cloning products and services to customers world wide, including major genome centers, universities, government research institutions, and industrial R&D facilities. Using its proprietary and patented gene cloning technologies, Lucigen is in the process of discovering and manufacturing unique enzymes for use in many markets, including: biomedical research, diagnostics, pharmaceuticals, and bioethanol production (manufacturing ethanol from crops for use in gasoline). In 2004, the Company had more than $1M in revenues from sales and SBIR grants, and has little long-term debt. Lucigen successfully raised over $1M in its first SEC Regulation D equity private placement round.

Via NeighborhoodNetwork.com, every existing home within a metropolitan area will always be available for prospective home buyers to browse and indicate interest. All homeowners will have the opportunity to claim, manage and monitor their property profile through a Realtor sponsor. Realtors will pay for exclusive buyer collection and marketing sponsorships enabling homeowners to “Click2Sell™”, thus inviting "hot", interested, preapproved buyers to tour their home on a specific day with second showings on the second day. All offers are considered on the second day thus increasing the opportunity for a multiple offer situation. On day three, a "For Sale" sign with a "Sold" sign attached is placed in front of the home until closing.

Business Description: Nerites Corporation develops novel tissue repair products as well as advanced coatings for implanted medical devices based on unique “wet” adhesive compounds. These synthetic compounds are a breakthrough advance in biologically-compatible adhesives that provide completely new options for tissue repair and device coatings. Two patent applications have been filed, along with four provisional patents. The start-up team has arranged contract manufacturing and preliminary toxicology and pre-clinical testing.  The Company is in discussions with potential device partners.
Technology Description: Synthetic “wet” adhesive compounds based on Mussel Shell Adhesive Proteins (MAPs). Developed technologies include multiple adhesive formulations to adhere to both devices and various body tissues.  Various polymers have been developed as coatings of devices to reduce or eliminate biofouling.  Other polymers have been developed that result in formation of various hydrogels in situ that are bound to specific tissues.
Proprietary Description: Company produces the only known synthetic compounds with “wet” adhesive properties that offer provide: biocompatibility, in situ adhesion, adhesion to both wet and dry surfaces, flexible coating thickness and composition, drug-eluting capability, and multiple hydrogel formulations.
Market Size: Current tissue repair products are generally accepted as suboptimal: cyanoacrylates are toxic and fibrin-based adhesives are weak adhesives. Despite this, the current market for tissue adhesives is approximately $500M worldwide. An effective tissue sealant (replacing sutures) or bone adhesive (for small bone fractures) could tap un-met market needs exceeding $1B/yr. An effective anti-adhesion spray (to prevent post-surgical adhesions) would tap an un-met market need that could be as large as $10B/yr. Medical device coatings are currently a $250M market in the U.S., growing more than 25%/yr.  The market for anti biofouling coatings is for surgical devices and implants is greater than $1B

NOXILIZER, Inc. is an early stage medical technology company which is developing a unique gas-based sterilization and disinfection system. The Company's initial products will provide medical offices, hospitals, and manufacturers with safer and more flexible systems for sterilizing medical devices and instruments. Unlike alternatives, Noxilizer's system is fast, portable, scalable, and safe for a wide variety of plastics, metals, and electronics. The Company was founded in April 2004 by three serial entrepreneurs to commercialize Noxilizer's proprietary sterilization technology. They have fielded a seasoned management team of executives, scientists, and engineers with extensive experience building businesses from ideas through IPO, and taking medical products from the lab through FDA to market.

PlaCor, Inc. is a development stage company with proprietary technology for measuring the effect of anti-platelet drugs.  The company was formed in 2003 by four former executives from AVECOR Cardiovascular, Inc. to further develop a novel device to measure platelet reactivity.  In the US alone, tens of millions of people take aspirin and other anti-platelet drugs daily to prevent heart attacks and strokes.  Testing to ensure that these drugs are indeed working is a large, emerging market area.  The company has raised over $1.6 million in initial financing and is now seeking an additional $2.5 million (or greater) in 2005.  Proceeds will be used to complete product development, finish laboratory and clinical studies and obtain 510(k) approval.  Commercial launch is expected early in 2006.

Silicon Informatics, Inc.  Desktop Supercomputing, Workstation Prices  Silicon Informatics, Inc, is developing technology that will deliver the power of supercomputing to the desktop – directly to users of high value engineering, scientific and business applications.   Currently, these users rely upon servers or clusters of computers that are typically installed within corporate or departmental IT data centers.  Through our DSA-5000 deskside server appliance, users will be able to customize and launch compute-intensive and data-intensive applications within their own PC environment – independent of their IT data centers.   Our platform will offer the performance of large cluster computing at a fraction of the cost.

picture not available

Islet Technology, Inc. (ITI) is a cell therapy company focused on enabling the transition of islet transplantation from its current success within the context of human research trials to full clinical availability as a curative therapy for diabetes. ITI’s two patent protected technologies, islet isolation and islet encapsulation, are essential in preparing islet cells for successful transplantation. The market potential of providing islets for transplant center use is estimated to be $131 million in 2006, growing to $415 billion by 2015. ITI plans to file its Biologic License Application (BLA) to the FDA in 2H05 and gain approval to launch its first product, InsCellsÔ, in 2H06. InsCells are islet isolated from deceased human donors. Our follow-on product, CapCellsÔ, will launch in 2H10. CapCellsÔ are islets sourced from deceased and living donors and protected by a proprietary coating that allows islet transplantation without the use of immunosuppressive drugs. CapCellsÔ also enable the transplantation of islets sourced from non-humans (pigs) and from advances in bioengineering.

TBA

picture not available

TBA

TBA